States Reap Rewards From Solo Suits Against Pharma; Atypical Antipsychotics May Offer Test Cases
Executive SummaryFirst the federal government came knocking at their doors and then state attorneys general followed with claims of health care fraud. Now drug makers are dealing with another nemesis: states that file individual suits instead of joining multistate settlements.
You may also be interested in...
US Supreme Court denies J&J petition seeking review of South Carolina’s $124m judgment related to Risperdal marketing, giving state unfair trade practice laws a boost.
In case that could impact use of state unfair trade practices statutes, Janssen seeks Supreme Court review of South Carolina’s $124 million judgment for Risperdal labeling and Dear Doctor letter.
GSK filed suit against the attorney general of Louisiana seeking a court order prohibiting the state from using private counsel in litigation over Avandia marketing; the state is seeking more than $10 billion in penalties.